TCG Crossover Management, LLC

Q3 2025 13F Holdings

  • Location
    palo alto, CA
  • Num holdings

    40

  • Value ($000)

    $2,032,902

  • Date Filed
    11/17/2025
  • Form type
    13F-HR
  • CIK
    0001839948
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

ABIVAX SA AMERICAN DEPOSITARY SHARES

ADRS
00370M103
$603.77M
30 %

7,111,596

C
CGON

CG ONCOLOGY INC

COMM
156944100
$147.84M
7 %

3,670,206

C
COGT

COGENT BIOSCIENCES INC

COMM
19240Q201
$97.62M
5 %

6,798,162

A
AMLX

AMYLYX PHARMACEUTICALS INC

COMM
03237H101
$84.85M
4 %

6,243,812

C
CNTA

CENTESSA PHARMACEUTICALS PLC

ADRS
152309100
$76.06M
4 %

3,136,480

T
TNGX

TANGO THERAPEUTICS INC

COMM
87583X109
$71.70M
4 %

8,536,196

O
OCUL

OCULAR THERAPEUTIX INC

COMM
67576A100
$71.51M
4 %

6,117,232

D
DNTH

DIANTHUS THERAPEUTICS INC

COMM
252828108
$65.98M
3 %

1,676,624

---

TOURMALINE BIO INC

COMM
89157D105
$62.74M
3 %

1,311,783

D
DYN

DYNE THERAPEUTICS INC

COMM
26818M108
$58.38M
3 %

4,615,144

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 40